Efficacy of Yinzhihuang Granules and Entecavir on Hepatitis B-induced Cirrhosis

[Objectives]This study aimed to observe the efficacy and safety of Yinzhihuang granules and entecavir in the treatment of hepatitis B-induced cirrhosis.[Methods]Total 80 patients with decompensated hepatitis B-induced cirrhosis were evenly and randomly divided into two groups,treatment group and control group.The patients in the treatment group were given orally with 0.25 mg entecavir and 5000 mg Yinzhihuang granules once a day,and those in the control group were given orally with 0.5 mg entecavir once a day.The levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),hyaluronic acid(HA)and HBV DNA,the Child-Pugh score,and the positive situation of HBeAg in different groups were observed before treatment and 12,24,48 and 96 weeks after the treatment,respectively.[Results]The serum ALT,AST,HA and HBV DNA levels,the HBeAg positive rate,and the Child-Pugh score in the treatment and control groups were significantly improved after the treatment(P<0.05).The improvement of the above indicators in the treatment group at week 96 was significantly better than that in the control group(P<0.05).[Conclusions]The combination of Yinzhihuang granules and entecavir is superior to entecavir in the treatment of decompensated hepatitis B-induced cirrhosis.

Protective Effects of Yinzhihuang Combined with Metformin on Nonalcoholic Fatty Liver Diseases Based on PPAR-αSignaling Pathway

[Objectives]To explore the protective effects and mechanism of Yinzhihuang combined with metformin on nonalcoholic fatty liver diseases(NAFLD)based on PPAR-αsignaling pathway.[Methods]54 male SD rats were randomly divided into 2 groups,namely normal group(12 rats)and high-fat feed group(42 rats).After 8 weeks,2 rats were randomly selected from each group.After pathological examination confirmed the success of the NAFLD model,the high-fat feed group was divided into model group,Yinzhihuang(9000 mg/kg),metformin group(200 mg/kg),Yinzhihuang combined with metformin group(4500 mg/kg+100 mg/kg),10 rats in each group.Except the normal group and the model group,the other groups were given treatment drugs at the same time,one time a day,on the fifth weekend of the experiment,at the last time of administration,fasting but giving water for 16 h,then collected blood and liver tissue.Biochemical method was used to detect AST and ALT in serum and SOD,MDA,GSH-px biochemical indicators in liver tissue;enzyme-linked immunosorbent assay(ELISA)was used to detect the levels of TNF-α,IL-6 and TGF-βin liver tissue;Western blot was used to detect the expression of peroxisome proliferators-activated receptor-α(PPAR-α)protein in rat liver tissue.[Results]Compared with the model group,the serum levels of ALT,AST and MDA in liver tissue of model group rats were significantly increased;the levels of SOD and GSH-px in liver tissue were significantly increased;TNF-αand IL-6 and TGF-βcontents in liver tissue were significantly increased.[Conclusions]Both Yinzhihuang and metformin have a therapeutic effect on NAFLD rats,and the effect of combined application of the two is significantly better than the intervention effect of Yinzhihuang or metformin alone,the mechanism is possibly associated with the regulation of PPAR-αsignaling pathway.

Effects of Yinzhihuang oral liquid and albumin on bilirubin, inflammatory factors, immune indexes and related factors in neonatal pathologic jaundice

Objective: To explore the effects of Yinzhihuang oral liquid and albumin on bilirubin, inflammatory factors, immune indexes and related factors in neonatal pathologic jaundice. Methods: A total of 134 neonates with pathologic jaundice admitted to our hospital from May 2017 to April 2018 were randomly selected as the control group (n=67) and the observation group (n=67), the control group was treated with albumin, the observation group was treated with Yinzhihuang Oral Liquid on the basis of the control group. The bilirubin, inflammatory factors, immune indicators, alpha-fetoprotein (AFP) and transferrin (TRF) were compared and analyzed before and after treatment. Results: After treatment, the levels of TBIL, DBIL and IBIL in both groups were significantly lower than those before treatment (P<0.05), and the levels of TBIL, DBIL and IBIL [(118.60±10.85) μmol/L, (6.95±1.52) μmol/L, (115.30±14.20)μmol/L] in observation group were significantly lower than those in control group;the levels of CRP and IL-6 in both groups were significantly lower than those before treatment (P<0.05), and the levels of CRP and IL-6 [(8.26±2.07) mg/L, (12.69±2.15) pg/mL] in observation group were significantly lower than those in control group (P<0.05);the levels of CD4+, CD4+/CD8+ in both groups were significantly higher than those before treatment (P<0.05), while the levels of CD8+ was significantly lower than that before treatment, the levels of CD4+, CD4+/CD8+ [(47.08±5.70)%, (2.08±0.41)] in observation group were significantly higher than those in control group (P<0.05), and the level of CD8+ [(22.90±2.05)%] was significantly lower than that in control group (P<0.05);the levels of AFP in significantly higher than before treatment (P<0.05), and the levels of AFP [(12.69±3.04)mg/L] in observation group were significantly lower than those in control group (P<0.05), the levels of TRF [(2.02±0.35) g/L] were significantly higher than those in control group (P<0.05). Conclusions: The combination of Yinzhihuang oral liquid and albumin can effectively reduce the bilirubin level in neonatal jaundice, inhibit its inflammatory reaction, enhance the cellular immune function and improve the expression of AFP and TRF, which is of clinical significance.

Study on the mechanism of Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules for neonatal jaundice treatment

Objective:To observe the mechanism of Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules for neonatal jaundice treatment and offer clinical help to neonatal jaundice treatment. Methods:80 children with neonatal jaundice were selected and randomly divided into groups:the observation group (40 children) and the control group (40 children). The patient in the control group were treated with blue light and the patients in the observation group were treated with Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules. Biochemical parameters [TBA (total bile acid), TSB (serum total bilirubin), DB (Direct bilirubin) and TCB (Percutaneous jaundice index)], nerve factor [NSE (neuronspecific enolase), Aβ(βamyloid protein) and S100B (Astrocyte derived protein)] and myocardial enzyme spectrum [LDH (lactate dehydrogenase), CK (creatine kinase) and CK-MB (isoenzymes of creatine kinase)], liver function [ALT (Alanine aminotransferase) and AST (glutamic-oxalacetic transaminase)] and renal function (BUN and Cr) were detected and analyzed before and after treatment. Results:The comparison of Biochemical parameters, nerve factor and myocardial enzymes, liver function and renal function in the two groups before treatment were not statistically significant (P>0.05). Biochemical parameters (TBA, TSB, TCB and DB), nerve factor (NSE, Aβand S100B) and myocardial enzyme spectrum (LDH, CK and CK-MB), liver function (ALT and AST) and renal function [BUN (urea nitrogen) and Cr (creatinine)] in both groups after treatment significantly decreased compared with that before treatment. The changes were statistically significant (P<0.05). Biochemical parameters (TBA, TSB, TCB and DB), nerve factor (NSE, Aβand S100B) and myocardial enzyme spectrum (LDH, CK and CK-MB), liver function (ALT and AST) and renal function (BUN and Cr) in observation group after treatment decreased more significantly compared with that in control group. The difference between two groups was considered to be statistically significant (P<0.05). Conclusions:Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules could regulate the Biochemical parameters, protect nerve function and cardiac muscle cells and improve liver and kidney function in newborns with jaundice. So it has a very important clinical significance of the treatment to neonatal jaundice.

茵栀黄口服液联合间断蓝光照射治疗新生儿高胆红素血症的临床效果分析

目的探讨茵栀黄联合间断蓝光治疗新生儿高胆红素血症的临床疗效。方法简单随机选取2021年1月—2022年12月丰县人民医院收治的新生儿病理性黄疸100例为研究对象,根据随机数表法分成两组,各50例,对照组采取蓝光治疗,观察组采取蓝光联合茵栀黄治疗,比较两组临床疗效、中医症候评分、血清胆红素水平及不良反应发生率。结果观察组疗效为96.00%,高于对照组的80.00%,差异有统计学意义(χ^(2)=4.640,P=0.031);治疗后,观察组的血清的中医症候评分低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的血清胆红素水平低于对照组,差异有统计学意义(P<0.05);治疗期间两组的不良反应的发生率比较,差异无统计学意义(P>0.05)。结论茵栀黄口服液联合间断蓝光照射治疗新生儿高胆红素血症可提高治疗效果,促进胆红素排泄,改善临床症状,且安全性高。

茵栀黄颗粒治疗3610例黄疸患者的真实世界临床联合用药特征分析

目的对真实世界进行定向数据挖掘,针对茵栀黄颗粒治疗黄疸的临床方案特征进行分析,探索茵栀黄颗粒治疗黄疸的联合用药方案。方法从真实世界15家医院信息系统(hospital information system,HIS)中提取3610例使用茵栀黄颗粒治疗黄疸患者的个人、住院及用药情况,标准化数据后以关联规则数据挖掘方式得出临床中使用茵栀黄颗粒治疗黄疸的联合用药方案;结果3610例患者各年龄段均有发病,以45~65岁占比最多(1242例,占34.40%),均为男性多于女性。联合用药情况:茵栀黄颗粒主要联用西药胸腺肽、地塞米松、甘草酸、苯巴比妥、奥美拉唑、中药柴胡注射液、感冒清热颗粒、苦黄注射液、康复新液、结核丸,用药类别为西药抗菌药、肝胆疾病治疗药、免疫促进药,中药解表剂、清热剂、扶正剂。常见一般性黄疸治疗用药方案:茵栀黄颗粒+苦黄注射液+甘草酸;茵栀黄颗粒+甘草酸+胸腺肽+苦黄注射液;抗结核药物相关肝损害所致黄疸协同治疗用药方案:茵栀黄颗粒+结核丸+康复新液+乙胺丁醇;茵栀黄颗粒+吡嗪酰胺+利福平+乙胺丁醇+康复新液;常见的用药类别联合方案:茵栀黄颗粒+清热剂+肝、胆疾病治疗药;茵栀黄颗粒+肝、胆疾病治疗药+免疫促进药+抗菌药+清热剂;茵栀黄颗粒+解表剂+清热剂+抗菌药;茵栀黄颗粒+扶正剂+解表剂+清热剂+抗菌药。结论治疗一般性黄疸,临床常采用的治疗方案为茵栀黄颗粒联合苦黄注射液+甘草酸和茵栀黄颗粒联合苦黄注射液+甘草酸+胸腺肽;对于长期服用抗结核药物引起的黄疸,常用的治疗方案为茵栀黄颗粒联合结核丸+康复新液+乙胺丁醇和茵栀黄颗粒联合吡嗪酰胺+利福平+乙胺丁醇+康复新液。

Clinical Observation of Yinzhihuang Oral Liquid(茵栀黄口服液) on Prevention of the Premature Infantile Jaundice

Objective:To observe the clinical efficacy of Yinzhihuang Oral Liquid(YOL,茵栀黄口服液)to prevent the premature infantile jaundice.Methods:After excluded hemolytic,suffocation,infection,and the very low birth weight,242 cases of premature infants were randomly assigned to two groups,the treatment group and the control group.Both groups were taken conventional procedures,such as warmth,feeding,and blood glucose monitoring,and the treated group was administered YOL 5 mL each time,twice daily additionally,and the co...

茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸的临床疗效

目的:探讨茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸的临床疗效。方法:选取2021年6月至2023年6月杞县妇幼保健院收治的94例感染性黄疸新生儿作为研究对象,随机数字表法分为茵栀黄联合组和常规治疗组,各47例。常规治疗组采用常规的蓝光照射和头孢哌酮钠舒巴坦钠抗感染治疗;茵栀黄联合组在常规治疗的基础上联合茵栀黄口服液治疗。治疗7 d后,比较两组临床总有效率、黄疸消退时间、住院时间、胆红素下降值、神经行为能力[新生儿神经行为测定评分系统(Neonatal behavioral neurological assessment,NBNA)]、免疫球蛋白(Immunoglobulin,Ig)A、IgG水平、胆红素相关指标[血清白蛋白(Albumin,ALB)、非结合胆红素(Unconjugated bilirubin,UCB)、总胆红素(Total bilirubin,TBIL)水平]及不良反应发生率。结果:治疗后,茵栀黄联合组总有效率明显高于常规治疗组(P<0.05);茵栀黄联合组黄疸消退时间、住院时间明显短于常规治疗组,每日胆红素下降值明显大于常规治疗组(P<0.05);茵栀黄联合组血清IgA、IgG水平及NBNA评分均明显高于常规治疗组(P<0.05);茵栀黄联合组ALB、UCB、TBIL水平均明显低于常规治疗组(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论:茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸疗效显著,可进一步缩短黄疸消退的时间,降低胆红素相关指标水平,提高患儿免疫功能和神经行为能力,加快患儿康复进程。

经络抚触配合茵栀黄颗粒对新生儿高胆红素血症血清乳酸脱羟酶和神经元特异性烯纯化酶及胱抑素C水平的影响

目的探讨经络抚触配合茵栀黄颗粒对新生儿高胆红素血症血清乳酸脱羟酶(LDH)、神经元特异性烯纯化酶(NSE)、胱抑素C(CysC)水平的影响。方法选取2019年1月至2021年12月德兴市人民医院收治的80例新生儿高胆红素血症患儿作为研究对象,按就诊时间分为研究组与对照组,每组40例。两组均接受常规对症治疗,在此基础上,对照组给予茵栀黄颗粒治疗,研究组给予经络抚触配合茵栀黄颗粒治疗。比较两组血清总胆红素(TBiL)水平、临床疗效、血清LDH、NSE、CysC水平及生长发育指标。结果治疗后,研究组血清TBiL水平低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清LDH、NSE、CysC水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组体质量重于治疗前,奶摄入量、大便次数均多于治疗前,睡眠时间长于治疗前,且研究组体质量重于对照组,奶摄入量、大便次数均多于对照组,睡眠时间长于对照组,差异有统计学意义(P<0.05)。结论经络抚触配合茵栀黄颗粒治疗新生儿高胆红素血症治疗效果更佳,可显著降低血清TBiL、LDH、NSE、CysC水平,促进患儿生长发育。

茵栀黄口服液联合双歧杆菌四联活菌治疗新生儿黄疸的效果

目的分析茵栀黄口服液联合双歧杆菌四联活菌应用在新生儿黄疸中的效果。方法选择山东省梁山县人民医院儿科自2021年6月至2023年10月期间收治的80例黄疸儿作为观察对象,依据随机数字表法进行分组,即对照组(40例,双歧杆菌四联活菌)和观察组(40例,茵栀黄口服液联合双歧杆菌四联活菌),对比两组不同治疗方案的作用效果。结果治疗后,其观察组的黄疸消失时间、胆红素及大便恢复正常时间等指标均优于对照组,(P<0.05);观察组治疗总有效率为97.50%显著高于对照组的85.00%,两组间差异明显(P<0.05);比较两组的并发症情况,观察组的并发症例数有2例,占比5.00%,对照组的并发症发生例数有9例,占比22.50%,组间差异显著(P<0.05)。结论茵栀黄口服液联合双歧杆菌四联活菌在新生儿黄疸中均有较高的应用价值,不仅提高了临床治疗效果,还促进其临床症状的改善,其不良反应也有所降低,可加速其康复进度。

清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病临床观察

目的探讨清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病的临床疗效。方法选取医院2021年3月至2023年3月收治的酒精性肝病患者200例,按随机数字表法分为观察组和对照组,各100例。两组患者均予酒精性肝病的基础治疗,对照组患者加用茵栀黄颗粒,观察组患者在对照组治疗基础上加用清肝化湿活血汤加减。两组患者均治疗12周。结果观察组总有效率为91.00%,显著高于对照组的79.00%(P<0.05)。治疗后,观察组患者肋痛胀满、痞块结坚、乏力纳呆、舌红苔黄的中医证候积分均显著低于对照组(P<0.05);观察组患者的丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、碱性磷酸酶、总胆红素水平均显著低于对照组(P<0.05);观察组患者的肝门静脉血流动力学指标最大流速、平均流速、搏动指数均显著高于对照组(P<0.05),阻力指数显著低于对照组(P<0.05);观察组患者的血清炎性因子白细胞介素17A、前列腺素E_(2)、CXC趋化因子配体13水平均显著低于对照组(P<0.05);观察组患者的欧洲研究与治疗组织生活满意度测定量表(EORTCQLQ-C30)躯体功能、角色功能、社会功能、总体健康评分均显著高于对照组(P<0.05)。治疗期间,观察组和对照组不良反应发生率相当(12.00%比8.00%,P>0.05)。结论清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病的临床疗效良好,可改善患者的中医证候积分和肝功能、肝门静脉血流动力学指标,降低炎性因子水平,且安全性良好。

茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸临床研究

目的:观察茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸的疗效,并分析该联合疗法对患儿肝功能的影响。方法:回顾性分析100例新生儿黄疸患儿的临床资料,按照不同治疗方案分为常规治疗组和茵栀黄治疗组各50例。常规治疗组予以蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗;茵栀黄治疗组在常规治疗组基础上给予茵栀黄口服液口服治疗。2组均治疗7 d。比较2组临床疗效、住院时间、胎便排空时间及不良反应发生情况,比较2组治疗前后胆红素和肝功能指标水平。结果:茵栀黄治疗组总有效率96.00%,高于常规治疗组84.00%(P<0.05)。治疗后,2组血清直接胆红素(DBil)、间接胆红素(IBil)、总胆红素(TBil)水平均下降(P<0.05),且茵栀黄治疗组低于常规治疗组(P<0.05)。治疗后,2组血清谷氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)及碱性磷酸酶(ALP)水平均降低(P<0.05),且茵栀黄治疗组低于常规治疗组(P<0.05)。茵栀黄治疗组患儿的住院时间、胎便排空时间均短于常规治疗组(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:采用茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸能够提高临床疗效,保护患儿肝功能,降低胆红素水平和不良反应的发生。

A Study of the Mechanism of Yinzhihuang（菌栀黄）Injection in the Treatment of Infantile Hepatitis Syndrome

The content of serum total bilirubin, serum alanine aminotransferase and hepatic enlarge-ment were observed before and affer the treatment for intantile hepatitis syndrome by using injections ofYinzhihuang. Peripheral blood T cell subproportions and levels of duodenal bilirubin were also detected insome patients. The results of this study suggest the injections of Yinzhihuang had a significant effect in re-solving jaundice, but no effect in improving the disturbance of cellular immunity.

茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果

目的探讨茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果。方法选取伊犁哈萨克自治州奎屯医院2020年1月至2022年12月的80例新生儿感染性黄疸患儿作为研究对象,按照随机数字表法分为对照组和观察组,每组各40例。对照组采用哌拉西林钠他唑巴坦钠治疗,观察组采用茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗。比较两组临床疗效、黄疸指数和心肌酶谱指标及不良反应发生情况。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清总胆红素、乳酸脱氢酶、总胆汁酸、肌酸激酶同工酶和经皮测胆红素水平均降低,且观察组水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果较好,值得推广。

新生儿黄疸的两种治疗方法比较:一项单中心回顾性病例对照研究

目的观察两种不同疗法对新生儿病理性黄疸胆红素、炎性因子含量及不良反应的影响。方法回顾性分析2020年7月—2022年1月到承德市中心医院新生儿科就诊的80例新生儿黄疸患儿的临床资料,按照自愿原则分为外用光照组和口服药物组,外用光照组患儿采用蓝光照射治疗,口服药物组在外用光照组治疗基础上予以茵栀黄颗粒联合双歧杆菌四联活菌片口服治疗。观察比较两组患儿血清胆红素和炎症指标含量、皮肤黄染消退所用时长和不良反应等情况,评价该联合治疗方式的有效性和安全性。结果外用光照组的有效率为80.00%(32/40),口服药物组的有效率为95.00%(38/40),与外用光照组比较,口服药物组的有效率明显升高。治疗开始前,外用光照组和口服药物组患儿的经皮胆红素水平无明显差异。治疗1个疗程后,与外用光照组比较,口服药物组患儿的经皮胆红素水平明显下降、黄染消退的时间显著减少(P<0.01,P<0.05)。与外用光照组比较,口服药物组患儿的血清胆红素含量显著减少(P<0.01)。治疗开始前,外用光照组和口服药物组患儿的谷草转氨酶(aspartate aminotransferase,AST)、谷氨酰转移酶(gamma-glutamyltransferase,GGT)以及碱性磷酸酶(alkaline phosphatase,ALP)水平无明显差异。治疗1个疗程后,与外用光照组比较,口服药物组患儿的GGT、ALP以及AST水平明显下降(P<0.01)。治疗开始前,外用光照组和口服药物组患儿的转铁蛋白(transferrin,TRF)、C-反应蛋白(C-reactive protein,CRP)以及甲胎蛋白(alpha fetoprotein,AFP)水平无明显差异。治疗1个疗程后,与外用光照组比较,口服药物组患儿的CRP、AFP以及TRF水平明显下降,差异具有统计学意义(P<0.01)。与外用光照组比较,口服药物组患儿发热、腹泻以及皮疹的发生率无明显升高(P>0.05)。结论茵栀黄颗粒、双歧杆菌四联活菌片能够更快速地减少新生儿黄疸患儿低经皮和血清胆红素含量,其作用途径与减少血清CRP、AFP水平,抑制患儿体内炎症反应相关。

茵栀黄口服联合间隙蓝光照射佐以双歧杆菌三联活菌对新生儿黄疸的效果研究

目的 探究茵栀黄口服联合间隙蓝光照射佐以双歧杆菌三联活菌治疗新生儿黄疸的效果。方法 随机选择2020年5月—2022年9月东台市人民医院儿科收治的新生儿黄疸患儿112例为研究对象,按照信封法分为对照组(常规治疗)及治疗组(茵栀黄口服联合间隙蓝光照射佐以双歧杆菌三联活菌治疗),各56例。比较两组临床疗效。结果 与对照组临床治疗总有效率(89.29%)相比,治疗组(100.00%)更高,差异有统计学意义(χ^(2)=4.403,P=0.036)。治疗后,两组经皮胆红素水平均低于治疗前,且治疗组经皮胆红素水平为(124.81±17.78)μmol/L,低于对照组,差异有统计学意义(P<0.05)。相较于对照组,治疗组不良反应总发生率(5.36%)更低,差异有统计学意义(χ^(2)=5.224,P=0.022)。结论 新生儿黄疸患儿治疗期间,通过茵栀黄口服联合间隙蓝光照射佐以双歧杆菌三联活菌治疗,可提高临床治疗效果,改善经皮胆红素水平,减少不良反应发生率。

基于网络药理学及分子对接探究茵栀黄颗粒治疗肝纤维化的作用机制

运用网络药理学及分子对接方法,探讨茵栀黄颗粒治疗肝纤维化的作用机制。通过中药系统药理学数据库与分析平台,对茵栀黄颗粒中4味药材进行活性成分筛选,利用SwissTargetPrediction数据库进行靶点预测;在GeneCards数据库中进行检索,获取肝纤维化相关的靶点,构建维恩图;运用DAVID数据库进行GO(gene ontology)功能和KEGG(Kyoto encyclopedia of genes and genomes)通路富集分析,运用Cytoscape3.9.0软件绘制成分-靶点网络图和靶点-通路网络图,通过STRING数据库与Cytoscape软件构建蛋白质-蛋白质相互作用网络图,利用AutoDock Tools对关键活性成分和核心靶点进行分子对接,验证网络药理学分析结果。通过口服生物利用度和类药性参数筛选出茵栀黄颗粒中的43个活性成分,肝纤维化相关靶点111个;GO功能富集分析得到生物过程条目346个,细胞组成条目32个,分子功能条目76个;KEGG通路富集分析筛选得到96条(P<0.05)信号通路,主要涉及PI3K-Akt信号通路、乙型肝炎、丙型肝炎、TNF信号通路等;分子对接显示茵栀黄颗粒中β-谷甾醇、木犀草素、山柰酚等与6个核心靶蛋白STAT3、AKT1、IL-6、TNF、EGFR、SRC均具有较好的亲和力。研究结果揭示茵栀黄颗粒多成分作用于多靶点,参与多通路的调控,通过抗炎、抑制氧化应激反应和抑制肝星状细胞的活化等发挥治疗肝纤维化的作用机制,该研究为进一步验证茵栀黄颗粒治疗肝纤维化的相关靶点及通路提供了依据。

中药药浴联合茵栀黄口服液治疗新生儿黄疸临床观察及对免疫功能的干预效果

目的探究中药药浴联合茵栀黄口服液治疗新生儿黄疸及对免疫功能干预的效果。方法选取2020年1月至2022年6月江西省儿童医院收治的60例新生儿黄疸患儿,按随机数字表法分为两组,各30例。对照组采取常规蓝光治疗,治疗组在此基础上采取中药药浴联合茵栀黄口服液治疗,比较两组治疗效果,免疫功能[T淋巴细胞(CD4+、CD8+、CD4+/CD8+),免疫球蛋白(Ig)G、IgA],不良反应。结果治疗组的总有效率较对照组高(P<0.05)。治疗5 d,两组CD4+、CD4+/CD8+、IgG、IgA较治疗前高,治疗组较对照组高,CD8+较治疗前低,治疗组较对照组低(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论中药药浴联合茵栀黄口服液可提高新生儿黄疸蓝光治疗效果,改善患儿免疫功能,且不增加不良反应。

茵栀黄口服液联合蓝光照射在新生儿黄疸中的效果分析

目的:探讨茵栀黄口服液联合蓝光照射对新生儿黄疸患儿心肌酶谱、免疫功能及黄疸指数的影响,并评估其用药安全性。方法:选取2020年1月~2020年12月期间本院收治的120例新生儿黄疸患儿作为研究对象,采用随机数字表法分为对照组和观察组,每组60例。对照组给予蓝光照射的治疗方法,观察组在对照组的基础上加用茵栀黄口服液,持续治疗5天。比较两组治疗的一般情况及治疗前后新生儿黄疸患儿心肌酶谱指标[肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、α-羟丁酸脱氢酶(α-HBDH)、乳酸脱氢酶(LDH)]、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+))水平及黄疸指数,观察并记录两组治疗过程中不良反应的发生情况。结果:治疗5天后,观察组治疗总有效率(95.00%)高于对照组(81.67%,P<0.05);观察组黄疸消退时间、住院时间均短于对照组(P<0.05);两组黄疸指数均下降(P<0.05),且观察组低于对照组(P<0.05);两组CK、CK-MB、α-HBDH、LDH水平均降低(P<0.05),且观察组各指标水平均低于对照组(P<0.05);两组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)比值均升高(P<0.05),且观察组各指标水平均高于对照组(P<0.05);观察组不良反应总发生率(25.00%)高于对照组(23.33%),但两组比较无统计学差异(P>0.05)。结论:茵栀黄口服液联合蓝光照射对新生儿黄疸具有较好的临床疗效,可显著改善患儿心肌酶谱水平,提高患儿的免疫功能。

枯草杆菌二联活菌颗粒联合茵栀黄颗粒对中轻度新生儿黄疸患儿血清胆红素水平的影响

目的分析枯草杆菌二联活菌颗粒联合茵栀黄颗粒对中轻度新生儿黄疸患儿血清胆红素水平的影响。方法选取2020年1—12月本院收治的中100例轻度新生儿黄疸患儿作为研究对象,按照随机数字法分为参照组与联合组,各50例。参照组予以茵栀黄颗粒治疗,联合组予以枯草杆菌二联活菌颗粒联合茵栀黄颗粒治疗,比较两组治疗前后经皮胆红素和血清总胆红素水平、治疗起效时间、黄疸消退时间、临床疗效及不良反应发生情况。结果治疗前,两组经皮胆红素和血清总胆红素水平比较差异无统计学意义;治疗后,两组经皮胆红素、血清总胆红素水平均低于治前,且联合组低于参照组,差异有统计学意义(P<0.05)。联合组治疗起效时间和黄疸消退时间均短于参照组,差异有统计学意义(P<0.05)。联合组治疗总有效率为96.00%,高于参照组的80.00%,差异有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义。结论枯草杆菌二联活菌颗粒联合茵栀黄颗粒治疗中轻度新生儿黄疸效果确切,有利于促进患儿血清胆红素水平恢复,加速病情康复,且安全性较高。